The National Brain Tumor Society is providing $200,000 to Oncoceutics to support a phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist, in a molecular subset of high grade gliomas.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
